D-1553

Phase 2Small molecule

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

D-1553 is one of 88 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

KRAS G12C Mutant Advanced Solid TumorsNot yet recruiting

Solid TumorsActive, not recruiting

Solid TumorPreclinical

Active, not recruiting

KRAS G12C Mutant Advanced Solid TumorsPhase 2

Not yet recruiting

Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

D-1553

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 8

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06300177

Phase 1/2Not yet recruiting

KRAS G12C Mutant Advanced Solid Tumors

NCT06435455

Q3 2029

PreclinicalActive, not recruiting

Solid Tumor

NCT05379946

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Terminated·IInventisBio Co., Ltd·Phase 1/2·NCT05492045·22 enrolled

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06300177·522 enrolled

KRAS G12C Mutant Advanced Solid Tumors1 trial

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Not yet recruiting·SSuzhou Genhouse Bio Co., Ltd.·Phase 1/2·NCT06435455·126 enrolled

Solid Tumors1 trial

Study to Evaluate D-1553 in Subjects With Solid Tumors

Active, not recruiting·IInventisBio Co., Ltd·Phase 1/2·NCT04585035·180 enrolled

Midazolam1 trial

A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Completed·IInventisBio Co., Ltd·Phase 1·NCT06105255·45 enrolled

Adult1 trial

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

Completed·IInventisBio Co., Ltd·Phase 1·NCT06233916·8 enrolled

2 more indications

Lung Cancer1 trial

Study to Evaluate D-1553 in Subjects With Lung Cancer

Completed·IInventisBio Co., Ltd·Phase 1/2·NCT05383898·225 enrolled

Solid Tumor1 trial

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Combination With IN10018 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

Active, not recruiting·IInventisBio Co., Ltd·Preclinical·NCT05379946·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for D-1553. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-1553 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-1553. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

D-1553

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

KRAS G12C Mutant Advanced Solid Tumors1 trial

Solid Tumors1 trial

Midazolam1 trial

Adult1 trial

Lung Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News